TY - JOUR
T1 - Paromomycin for cryptosporidiosis in aids
T2 - A prospective, double-blind trial
AU - Clinton White, A.
AU - Chappell, Cynthia L.
AU - Sikander Hayat, C.
AU - Kimball, Kay T.
AU - Flanigan, Timothy P.
AU - Goodgame, Richard W.
N1 - Funding Information:
Received I December 1993; revised 21 February 1994. Presented in part: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans. October 1993 (abstract 100). Informed consent was obtained from each patient enrolled in this trial. The trial was conducted under the guidelines of the Institutional Review Board of Baylor College of Medicine. Grant support: King Ranch Family Foundation. Drug and placebo but no financial support was provided by Parke-Davis. Reprints or correspondence: Dr. A. Clinton White, Jr., Dept. of Medicine. Baylor College of Medicine. I Baylor Plaza, Houston, TX 77030. *Present affiliations: University ofTexas School of Public Health. Houston (C.L.c.); Department ofYeterinary Parasitology, University of Agriculture, Faisalabad, Pakistan (C.S.H.).
PY - 1994/8
Y1 - 1994/8
N2 - To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 X 106 to 109 X 106 /24 h (P<.02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 X 106 /24 h for the 6 initially treated with drug (P<.02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P<.05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.
AB - To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 X 106 to 109 X 106 /24 h (P<.02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 X 106 /24 h for the 6 initially treated with drug (P<.02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P<.05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.
UR - http://www.scopus.com/inward/record.url?scp=0028238931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028238931&partnerID=8YFLogxK
U2 - 10.1093/infdis/170.2.419
DO - 10.1093/infdis/170.2.419
M3 - Article
C2 - 8035029
AN - SCOPUS:0028238931
SN - 0022-1899
VL - 170
SP - 419
EP - 424
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -